Alpha 1 Biomedicals, SciClone news
The companies settled their dispute over ALBM's Thymosin alpha 1 by granting SCLN virtual control over the product in return for up to $35 million in royalty payments
Gathering data...
The companies settled their dispute over ALBM's Thymosin alpha 1 by granting SCLN virtual control over the product in return for up to $35 million in royalty payments